Anavex Life Sciences Corp (AVXL)

[XenaLives]

Compiled Due Diligence 12/2/18

This is a wonderful board for collective effort, thanks to all who contribute. I have tried to organize this post as well as I could, suggestions and corrections are welcome.

Company website - upcoming and past events:
https://www.anavex.com/investor-material/events/

Company Website - presentations on line:
https://www.anavex.com/investor-material/
_________________________________________________________________________________________________________________________
NEW NEWS:
Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome
Study will incorporate genomic precision medicine ANAVEX®2-73-specific biomarkers
https://www.anavex.com/anavex-life-sciences-announces-fda-approval-of-ind-for-phase-2-trial-of-anavex2-73-in-patients-with-rett-syndrome/

Additional recent discussion under Rett Syndrome headline..

_________________________________________________________________________________________________________________________UPCOMING PRESENTATIONS AND OTHER POSSIBLE EVENTS:

Dec. 11 NYAS symposium, Alzheimer’s Disease Therapeutics: Alternatives to Amyloid, that Nell Rebowe is organizing with Dr. Rudy Tanzi and Dr. Howard Fillit of the Alzheimers's Drug Discovery Foundation.

https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979620
Pertinent comments on the above from TTAV: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144635533

Daniel Klamer will present a webinar, Precision Medicine in CNS Drug Development, on December 13th:

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled precision medicine to become a more viable treatment option. The next frontier in this type of medicine may be in the treatment of central nervous system disorders.

This webinar will evaluate the following:
• What lessons can we learn from the use of precision medicine in oncology?
• How has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s?
• What questions should you ask before you add a new biomarker to your clinical trial?
• What are the pros and cons of using biomarkers as surrogate endpoints?

https://resources.sharevault.com/webinar_precision-medicine-in-cns-drug-development (Thanks TTav)

February 19-21, 2019, Anavex will be participating in the 7th World CNS Summit - Targeting Neurodegenerative Diseases.
https://www.nyas.org/events/2018/alzheimer-s-disease-therapeutics-alternatives-to-amyloid/?tab=agenda
From the event’s description:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144414392

_________________________________________________________________________________________________________________________
Hampel Speaks!:

Harald Hampel may be the world's foremost authority on Alzheimer's. It is an honor to have him speak on behalf of Anavex.
https://www.alzforum.org/member-directory/harald-hampel-0

AAIC August 2018
htps://investorshub.advfn.com/boards/read_msg.aspx?message_id=142864055
(video and ad hoc transcript above)
Slides: https://www.anavex.com/wp-content/uploads/2018/07/Anavex-AAIC-2018-DT-01-Presentation.pdf

On Nov 10th, 16th Asian Oceanian Congress of Neurology (AOCN) - Coex, Seoul Korea -
Keynote presentation: Precision Medicine for Neurodegenerative Diseases- Harald Hampel
https://www.youtube.com/watch?v=olaYKyue1HM

Hampel at the VI International Congress on Research and Innovation in Neurodegenerative Diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143924640
Comments on the above: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921147

Hampel's new web site on precision medicine features his presentation on 2-73.
https://www.apmiscience.com/interviews
_________________________________________________________________________________________________________________________
PRESS AND THIRD PARTY COVERAGE:

Anavex and Ariana (thanks TTAV66)
"Ariana Pharma promoting their work with Anavex. Nice write up, including the further reading section where they point to the upcoming CTAD presentation and detail their full history of collaboration with Anavex. "
http://www.arianapharma.com/2018/09/alzheimer-precision-medicine/

Another article by Ariana Pharma on their website, this time highlighting the CTAD presentation:
http://www.arianapharma.com/2018/10/arianas-ai-demonstrate-clinical-efficacy-of-anavex2-73-for-alzheimers-patient-ctad-2018/

Thanks to polarbear for this link.. all I can say is "It's about time"...
https://alzheimersnewstoday.com/2018/10/31/anavex-2-73-slows-cognitive-decline-alzheimers-extension-study/

Press coverage of AVXL at 2018 CTAD:
http://cnafinance.com/anavex-life-sciences-avxl-stock-gaining-on-clinical-data/20696
http://www.bioworld.com/content/tiny-anavex-thinks-big-three-year-ad-data-ctad

Recent press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:
https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73

Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822
Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results

When the hugs and kisses stopped...
https://www.abc.net.au/news/2018-11-14/dementia-onset-when-the-hugs-stopped/10433574

Videos of Australian Patients from the P2a trial

UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909

From K9uwa aka John: Today in Parkinsons News Today ENROLLING NOW in Spain article.
http://parkinsonsnewstoday.com/2018/11/01/anavex-recruiting-parkinsons-dementia-patients-spain-anavex-2-73-trial/

_________________________________________________________________________________________________________________________
AUDIO PRESENTATIONS:

Cantor Fitzgerald Presentation from Cantor Fitzgerald Global Healthcare Conference October 3, 2018 2:50 p.m.
http://wsw.com/webcast/cantor7/avxl/

Comment on the above from dia76ca "At Cantor Dr. Missing said that the Rett trial would "clear VERY SOON"(At the 27:30 minute mark). We would do well to remember some of the other things he said.(e.g. Cash on hand for 2 years...21:21 minute mark ; Anavex 3-71 in clinic in 2019...29:34 minute mark ; Parkinson read-out in 2019...30:40 minute mark."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144349470

Additional audio presentations on the company web site see links at top of post.
_________________________________________________________________________________________________________________________
VIDEO PRESENTATIONS

Anavex SAB member Dr Paul Aisen speaks about PET Scans:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143921781

History of rettsyndrome.org featuring Christopher Missling:

Dr. Tangui Maurice on the Sigma 1 - 2015 video:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143980208

Additional video presentations on the company web site see links at top of post.

_________________________________________________________________________________________________________________________
SLIDE SHOWS AND POSTERS:

From TTTav: October Corporate Presentation used at the Cantor Fitzgerald Conference
https://www.anavex.com/wp-content/uploads/2018/10/Anavex-Presentation-Oct-2018.pdf

Dr Robert Lisak’s MS poster presented at the 2018 ECTRIMS conference:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144223191&txt2find=ectrims

CTAD 2018 slides - see the following grouping
_________________________________________________________________________________________________________________________
OCTOBER 2018 CTAD PRESENTATIONS:

Poster available during the duration of CTAD:
P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX®2-73 for the
Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen Macfarlane, MBBS FRANZCP1 , Michael Kornhauser BPharm1 , Ella Modini BSc1 , Harald Hampel, MD PhD2 , Stephan Toutain MS3, Christopher Missling PhD3

Friday, October 26 - Late Breaking Session
3.30 - 3.45 p.m. LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers
Harald Hampel, MD, PhD1 , Mohammad Afshar, MD, PhD2 , Frédéric Parmentier, PhD2 , Coralie Williams, MSc2 , Adrien Etcheto, MSc2 , Federico Goodsaid, PhD3 , Christopher U Missling, PhD4
****Information on Federico Goodsaid,Regulatory Pathfinders
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143696879
https://www.linkedin.com/in/regulatorypathfinders (Thanks blanka)

Saturday, October 27- Oral communications:
1.30 - 1.45 p.m. OC31 - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation Gustavo A. Jimenez-Maggiora, MBA1 , Rema Raman, PhD1 , Michael S. Rafii, MD, PhD1 , Reisa Anne Sperling, MD2,3, Jeffrey Lee Cummings, MD4, Paul S. Aisen, MD1

Slides from 2018 CTAD:
https://www.anavex.com/wp-content/uploads/2018/10/ANAVEX2-73_CTAD_2018_Presentation.pdf

Slide 16 shows good response in those with ApoE4 variant even though it is expected to be associated with faster rate of AD progression:
https://www.nature.com/articles/tpj200958
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144500445

Investor2014 on CTAD slides
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

CTAD overviews:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144493744
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495242

Some CTAD coverage:

_________________________________________________________________________________________________________________________
TRIAL PROCEDURE AND PROTOCOLS:

Arguments for accelerated approval for 2-73.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143620275
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143624077
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144651100
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144731123
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144982778

Provisional approval in Australia may not require completion of the P3.. (links thanks to JonJones325)
https://www.tga.gov.au/publication/provisional-determination-eligibility-criteria
https://www.tga.gov.au/publication/provisional-determination
https://www.tga.gov.au/presentation-provisional-approval-pathway-prescription-medicines

Definition of Major Therapeutic Advance in Australia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144734105

Precedents and legal pathways to approval from Biostockclub & Nidan:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166
Link from the above post naming precedents for drug approval without a Random Controlled Trial:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932294/#!po=95.1923

On ACTC participation in the U.S.:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144487503
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208260

New guidance for early stage Alzheimer's being developed in the U.S.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145208035

Current state of Alzheimer's fluid biomarkers. - Full Paper (from Investor2014)
https://link.springer.com/article/10.1007/s00401-018-1932-x

What is a Special Protocol Assessment?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140087471

Precision Medicine and “The Economics of Drug Development”
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144010889

How enrollment works:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144955802

The company's stated timeline for Alzheimer's P2b/3:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144956279

Missling states that PET scans will be used in P2/3 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143981335

On dosage of 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144631198
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144495639

Discussion of P2a trial dropouts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144496759


_________________________________________________________________________________________________________________________
ALZHEIMER'S TRIAL DISCUSSIONS AND UPDATES:


https://www.slideshare.net/TherapeuticGoodsAdministration/clinical-trials-tga-role

What does Donepezil do?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144744473

On the difficulty in diagnosing Alzheimer's:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145129244

French healthcare system decides it will no longer reimburse for Donepezil and other Alzheimer's drugs.
http://english.prescrire.org/en/81/168/55126/0/NewsDetails.aspx

How the U.S. is failing its people in healthcare:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145076878

Alzheimer's & SOC - too many patients exposed to drug interactions: French data:
http://english.prescrire.org/en/81/168/49338/0/NewsDetails.aspx

Basic biology concepts for Alzheimer’s disease
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137348423

Alzheimer's and Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134772774
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134771894

Falconer posts on sleep and Alzheimer's :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144599308
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135780296
(see also insomnia patent under IP)

Doc328 on Alzheimer's vaccines:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145066297

November 2018 publication on Sigma 1 - note the dates of publication history starting in 2016:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771390/pdf/CN-16-97.pdf

Comordbidity in Alzheimer's and dementia from nidan7500
https://alzheimersnewstoday.com/2018/11/14/comorbidities-common-disabling-in-alzheimers-and-dementia-patients-uk-study-finds/
More on comorbidity:
http://dare.ubvu.vu.nl/bitstream/handle/1871/15970/7839.pdf?sequence=5#page=77
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5417646/
https://academic.oup.com/ageing/advance-article/doi/10.1093/ageing/afy155/5133260

Of Mice and Men - Alzheimer's drug development through the years:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143978495

See also CTAD 2018 discussions in group above.
_________________________________________________________________________________________________________________________
PARKINSON'S DEMENTIA TRIAL DISCUSSIONS AND UPDATES:

How the Parkinson's Dementia trial may help expedite Alzheimer's approval:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143580569

Biostockclub on Parkinson's dosage:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144533102

Parkinson's News Today announces trial with participation of MJF foundation from whippensaw:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144653898

EU Parkinson's trail info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654071

Spanish trial info:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144654240


_________________________________________________________________________________________________________________________
RETT SYNDROME TRIAL DISCUSSIONS AND UPDATES:


Rett Syndrome trial and endpoints announced on Clinicaltrials.gov 11/29/18 (Thanks to poster Abel and Cabel)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164109

Info on Dr. Kaufmann who will be running the 2-73 Rett Syndrome trial:
http://gcbcenter.kennedykrieger.org/staff.jsp

Rett Syndrome in adults:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145216562

Rett Syndrome & Fragile x - they are are related:
From Talon38 (post 173314) "NIH's updated (2 days ago) information on Fragile X. Notice both the similarities and differences (predominantly a male diseases). Fragile X is one of 2-73's pipeline targets as is Infantile Spasms and Angelman's. Not a stretch to believe that Tayo Fadiran has been working CDER and NIH for a combined clinical trial approach to these orphan diseases. With positive Rett Syndrome results, that may come to fruition. The 2-73 "train" is gathering momentum!"
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome

Investor2014 reminds us of the Rett Syndrome Study Design:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701675
Discussion of Rett Trial Design why it is structured the way it is:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144356675
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205166

On the phases of Rett Syndrome:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144701046

Will the trial be moved to Australia?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144362026

On Rett Syndrome and the M4 Receptor from Investor2014:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144347886

Other Rett Syndrome related posts:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144357506
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135703149

Talon38 provided this NIH link on Rett Syndrome:
https://ghr.nlm.nih.gov/condition/rett-syndrome

dadofmarcmax on Rett Syndrome and other epileptic diseases:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135019599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135028269

Paper on Rett Syndrome treatment procedures:
https://pdfs.semanticscholar.org/c2c8/1063888a7aecffd3b1fe74a7b67496b2554f.pdf

The significance of Dr Andrew Cole MD authority on Epilepsy to Anavex SAB:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144358640

PennyDouble reminds us, we have an expert on the SAB :
https://www.anavex.com/anavex-life-sciences-appoints-distinguished-researcher-neurology-epilepsy-scientific-advisory-board/


_________________________________________________________________________________________________________________________
GUT and BRAIN:

HOMEOSTATIC NETWORKING: THE ROLE OF PHYTOCHEMISTRY, THE ENDOCANNABINOID SYSTEM AND POTENTIAL FUTURE THERAPEUTICS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144438361

Restoration of gut microbiota as MOA in a possibly competitive Chinese compound:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144442713

XenaLives posts on gut/brain:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443836
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144443854
_________________________________________________________________________________________________________________________[color=red]OTHER CNS ADDITIONAL INDICATIONS:
From dadofmarcmax, the linked site has TONS of info:
"Why does Anavex 2-73 have effects on seemingly different neuro-degenerative disorders? What makes it so special? "
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143816865

Fragile X is a growing concern (link from cninc):
https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00564/full

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144971728

dadofmarcmax on treatment of epilepsy with Anavex platform drugs:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=127872231
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131111781

Anavex also has Orphan Drug Designation for Infantile Spasms:
https://www.anavex.com/anavex-announces-u-s-fda-orphan-drug-designation-for-anavex-2-73-for-treatment-of-infantile-spasms/

_________________________________________________________________________________________________________________________[color=red]GENERAL MISC. DISCUSSIONS AND UPDATES:


An excellent summary of why we are here from poster sokol:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143320176

Sokol on Anavex's international strategies:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144504285

Link to PeterKarol's blog:
https://piotrpeterblog.com/

Short term milestone summary:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144330988

CRISPER discovery of likely MOA for 2-73:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144274561

Missling has a strategy - comments from posters on that strategy:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144051610
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144350599
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145164402

November 2018 - New SAB member Dr. Dag Aarsland, support for current and future pipeline:
https://globenewswire.com/news-release/2018/11/08/1647793/0/en/Anavex-Life-Sciences-Strengthens-its-Scientific-Advisory-Board-with-Distinguished-Researcher-for-Clinical-Treatment-of-Parkinson-s-Disease-Dementia-PDD.html

Charts showing periods of institutional accumulation:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144037184

Dangerous medicines and mitochondrial dysfunction:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142393634&txt2find=mitochondrial

Personal comments from falconer66a on the failure of traditional western medicine:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144979916

On Sleep:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135735670
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144599308

Perspective on how quickly Anavex could morph into a profitable entity , making further dilution unnecessary. This may provide urgency for institutions to establish a position where stock has limited liquidity resulting in a pre-approval ramp up of pricing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143560772

AVXL 2-73 and cerebral blood flow:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143582952

Brain cells from stem cells at Lund University:
https://www.lunduniversity.lu.se/article/new-method-grows-brain-cells-from-stem-cells-quickly-and-efficiently

Dr. Tanzi on infection and Alzheimer's, also "soda brain".
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143979877

Sokol with a 2016 perspective on potential Alzheimer's treatments:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144809093

b]Shareholder meeting report:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140128467&txt2find=shareholder|meeting

_________________________________________________________________________________________________________________________
Anavex IP protection:

Patent for Insomnia: (EN) A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION
Abstract:
(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg. (from basparks79)
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=173B4DDABFF25B0C26F75F5B8E98D703.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCT+Biblio

More on the patent for Insomnia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144833903
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144834373
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144842204

_________________________________________________________________________________________________________________________
GENERAL INFO ON TRIAL PROCEDURE AND FDA:

Check this out on retrospective validation: (from Nidan7500)
https://www.nature.com/articles/6500363#hypothetical-safety-example-seeking-drug-approval-in-the-dnasubgroup-of-patients-with-less-risk-of-a-cardiovascular-adverse-events-after-trial-completion

What’s in a p value? - a significant read! (from Investor2014)
http://www.evaluate.com/vantage/articles/analysis/vantage-views/whats-p-value
_________________________________________________________________________________________________________________________
Big Pharma, BIIB AND POTENTIAL PARTNER DISCUSSION:

Did BIIB blink?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143525102

BIIB's problem with Alzheimer's trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144801572

Bayer also bailing on R&D:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145174145

Why did Big Pharma bail on Alzheimer's trials early 2018? Possible Answer:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214094
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145215823

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214295

Anavex - Biogen & MS
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135630393
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143729928
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143732818
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143734046
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144040837